Clinical trials
PD-L1 Positive clinical trials
Below are recruiting pd-l1 positive clinical trials, each written for real people, not researchers. We’re tracking 62 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07055841RecruitingPhase 2
Study of PD-L1 antibody plus chemo before surgery for head and neck cancer
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
Jinan, ShandongAges 18–85 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07284992RecruitingPhase 2
Comparing short vs long radiation with immunotherapy for rectal cancer
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Jinan, ShandongAges 18–80 - NCT06012734RecruitingPhase 1
LB-100 plus Atezolizumab for metastatic colorectal cancer
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT07655622RecruitingPhase 1/Phase 2
Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Nanchang, JianxiAges 18–75 - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT06305962RecruitingEarly Phase 1
Radioactive drug for advanced PD-L1 positive solid tumors
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Kingswood, New South WalesAges 18 years+ - NCT06487624RecruitingPhase 1
Study of HCB301 for advanced solid tumors and Hodgkin lymphoma
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Greenville, South CarolinaAges 18 years+ - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT06423885RecruitingPhase 2
Study of BL-M07D1 combination for advanced HER2-positive stomach cancer
This study tests a new combination therapy (BL-M07D1 plus another drug) for people with advanced HER2-positive stomach or gastroesophageal junction cancer. It aims to see if the combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07209189RecruitingPhase 2
Chemo and immunotherapy before surgery for head and neck cancer
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
Baltimore, MarylandAges 18 years+
Hear when a new PD-L1 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-l1 positive?
- Yes. Clin2 currently lists 62 recruiting pd-l1 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-l1 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-l1 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.